1302 related articles for article (PubMed ID: 18619646)
1. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
5. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
8. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
10. The Role of β-Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical Study.
Geduk A; Atesoglu EB; Tarkun P; Mehtap O; Hacihanefioglu A; Demirsoy ET; Baydemir C
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):785-9. PubMed ID: 26422250
[TBL] [Abstract][Full Text] [Related]
11. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
12. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
14. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
15. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
16. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
18. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
19. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis.
Gebauer N; Bernard V; Gebauer W; Feller AC; Merz H
Acta Haematol; 2013; 129(4):251-6. PubMed ID: 23343777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
